直接口服抗凝药治疗期间急性硬膜下出血患者的管理
本研究为单中心回顾性分析,连续纳入30个月内因急性硬膜下出血且院前服用DOAC(n=65)或维生素K拮抗剂(n=63)的128例患者。主要结果显示,整体30天死亡率为27%,DOAC组与VKA组无差异(26% vs 27%,p=1.000);两组神经外科干预率(65%)和颅内再出血率(18%)相当。VKA组凝血酶原复合物使用频率高于DOAC组(90% vs 58%,p<0.0001)。作者认为这些发现支持DOAC在颅内出血情境下的良好安全性,但DOAC特异性拮抗剂的可用性可能进一步改善此类患者的管理。
要点
- DOAC相关急性SDH患者30天死亡率与VKA相当:DOAC组26% vs VKA组27%,p=1.000。
- 两组神经外科干预率均为65%,颅内再出血率均为18%,无差异。
- VKA组凝血酶原复合物使用率显著高于DOAC组:90% vs 58%,p<0.0001。
- 本中心30个月内连续纳入128例院前服用DOAC或VKA的急性SDH患者。
- 作者认为DOAC特异性拮抗剂的可用性可能进一步改善此类患者的管理。
适用人群与场景
- 本中心连续收治的急性硬膜下出血患者,院前正在接受DOAC(n=65)或VKA(n=63)抗凝治疗,共128例。
处置流程与药物剂量
- VKA组接受凝血酶原复合物的比例为90%,DOAC组为58%(p<0.0001)。
- 作者认为DOAC特异性拮抗剂的可用性可能进一步改善这些患者的管理。
研究设计与关键结果
- 研究类型:单中心回顾性队列分析,分析本中心30个月内连续收治的急性SDH且院前服用DOAC或VKA的患者医疗记录。
- 样本量:128例,其中DOAC组65例,VKA组63例。
- 主要终点:整体30天死亡率为27%,DOAC组26% vs VKA组27%(p=1.000),两组无差异。
- 关键次要终点:神经外科干预率两组均为65%,颅内再出血率两组均为18%,两组相当。
- 凝血酶原复合物使用:VKA组90% vs DOAC组58%(p<0.0001),VKA组使用更频繁。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于院前服用DOAC的急性SDH患者,本队列显示其30天死亡率与VKA组相当(26% vs 27%),神经外科干预率和再出血率亦相当,提示DOAC不增加院内及30天死亡风险。
- VKA组凝血酶原复合物使用率高于DOAC组(90% vs 58%),作者认为DOAC特异性拮抗剂的可用性可能进一步改善此类患者的管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Anticoagulation therapy is a major risk factor for unfavorable patient outcomes following (traumatic) intracranial hemorrhage. Direct oral anticoagulants (DOAC) are increasingly used for the prevention and treatment of thromboembolic diseases. Data on patients treated for acute subdural hemorrhage (SDH) during anticoagulation therapy with DOAC are limited.
METHODS: We analyzed the medical records of consecutive patients treated at our institution for acute SDH during anticoagulation therapy with DOAC or vitamin K antagonists (VKA) during a period of 30 months. Patient characteristics such as results of imaging and laboratory studies, treatment modalities and short-term patient outcomes were included.
RESULTS: A total of 128 patients with preadmission DOAC (n = 65) or VKA (n = 63) intake were compared. The overall 30-day mortality rate of this patient cohort was 27%, and it did not differ between patients with DOAC or VKA intake (26% vs. 27%; p = 1.000). Similarly, the rates of neurosurgical intervention (65%) and intracranial re-hemorrhage (18%) were comparable. Prothrombin complex concentrates were administered more frequently in patients with VKA intake than in patients with DOAC intake (90% vs. 58%; p < 0.0001). DOAC treatment in patients with acute SDH did not increase in-hospital and 30-day mortality rates compared to VKA treatment.
CONCLUSIONS: These findings support the favorable safety profile of DOAC in patients, even in the setting of intracranial hemorrhage. However, the availability of specific antidotes to DOAC may further improve the management of these patients.
参考来源
- Beynon C, Brenner S, Younsi A, et al. Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants. Neurocrit Care. 2019. PMID: 30382531. doi:10.1007/s12028-018-0635-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。